Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Researchers Discover New Type of Neuron that Plays Key Role in Nicotine Addiction

November 24, 2014 – 7:00 am | Edit Post

“If we can find a way to target those neurons in humans, maybe we can reduce the ‘high’ produced by the drug and reduce the withdrawal symptoms,” says Assistant Professor Olivier George.

Team Reveals Weak Spots in Ebola’s Defenses

November 24, 2014 – 7:00 am | Edit Post

The new study from the Ward and Saphire labs exposes how experimental drug ZMapp attacks the virus and suggests strategies to improve future therapies.

Cells’ Response to Chronic Protein Misfolding May Do More Harm than Good

November 24, 2014 – 7:00 am | Edit Post

The study from the Balch lab suggests diseases such as cystic fibrosis and Alzheimer’s can be seriously exacerbated by the body’s response, providing fundamental insights with implications for the design of new therapies.

Physician-Scientist Shares his Journey to Help Those with Autoimmune Diseases

November 24, 2014 – 7:00 am | Edit Post

Professor Hugh Rosen spoke to donors about his experiences with drug discovery at a recent lecture hosted by TSRI’s Office of Philanthropy.

Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference

November 24, 2014 – 5:39 am | Edit Post

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2014 /PRNewswire/ – Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present in a fireside chat discussion at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 12:30 p.m. ET in New York.

The live audio webcast and subsequent replay may be accessed by visiting Veracyte’s website at http://investor.veracyte.com. Please connect to the website at least 15 minutes prior to the live webcast to ensure adequate time for any necessary software download. The webcast will be available shortly after conclusion of the presentation and archived on the company’s website for 14 days following the presentation.

About Veracyte

Veracyte (Nasdaq: VCYT) is pioneering the field of molecular cytology, focusing on genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte’s first commercial solution, the Afirma® Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier (GEC) to resolve ambiguity in diagnosis and is becoming a new standard of care in thyroid nodule assessment. Since launching its Afirma solution in 2011, Veracyte estimates it has helped approximately 10,000 patients with thyroid nodules avoid unnecessary surgery, reducing healthcare costs by millions of dollars. Afirma is recommended in leading practice guidelines and is covered for more than 135 million lives in the United States, including through Medicare and most commercial insurance plans. Veracyte intends to expand its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. The company is in late product development for a genomic test to resolve preoperative ambiguity in lung nodules that are suspicious for cancer. Veracyte is also developing a second product in pulmonology, targeting interstitial lung diseases that include idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.

Veracyte, Afirma, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc. This press release also contains trademarks and trade names that are the property of their respective owners.

Media:Tracy Morris650-380-4413 Tracy.Morris@Veracyte.com

Investors:Angeli KolhatkarBurns McClellan, Inc.212-213-0006akolhatkar@burnsmc.com  

SOURCE Veracyte

Nicotine addiction linked to neuron

November 22, 2014 – 2:25 pm | Edit Post

A newly discovered kind of neuron unites the buzz of nicotine and withdrawal pangs.

Aurora Spine to Present at Brean Capital Life Sciences Summit Conference

November 22, 2014 – 7:01 am | Edit Post

CARLSBAD, CALIFORNIA–(Marketwired – Nov. 22, 2014) – Aurora Spine Corporation (TSX VENTURE:ASG) announced today that it will be presenting at the Brean Capital Life Sciences Summit Conference in New York, NY on November 24, 2014. Brean Capital’s Corporate Access product offering includes a number of industry-specific and regional “best idea” investment conferences to facilitate the interaction of company management and institutional investors throughout the year.

Ichor Wields Weapon in Biological Threat Fight

November 21, 2014 – 11:33 am | Edit Post

Ichor Medical Systems Inc., a San Diego-based biotech, recently was awarded funding potentially worth $20.2 million over five years from a national defense organization to develop a special kind of immunization to protect U.S. military members and the general population against biological threats.

Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015

November 21, 2014 – 6:30 am | Edit Post

SARASOTA, Fla., Nov. 21, 2014 /PRNewswire/ – Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company is scheduled to present at the Biotech Showcase™ 2015 taking place in San Francisco, CA on January 12-14, 2015.

Michael Mullan, MBBS, PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will present preclinical and clinical data for anatabine citrate, a small molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. Dr. Mullan will outline the Company’s regulatory strategy and ongoing drug development initiatives designed to advance its the lead molecule into phase I and phase II trials.

About Biotech Showcase 2015:

Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week, which is widely viewed as setting the tone for the coming year.

About Anatabine Citrate:

Rock Creek Pharmaceuticals’ anatabine citrate is a small molecule, cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. The Company has sponsored extensive pre-clinical (in vitro and in vivo) studies resulting in peer reviewed and published scientific journal articles, covering models of Multiple Sclerosis, Alzheimer’s Disease, and Auto-Immune Thyroiditis. All these studies demonstrated the anti-inflammatory effects of anatabine. In addition, the Company’s compilation of human exposure, safety and tolerability data, derived primarily from human clinical studies and post-marketing data collection of the previously marketed nutraceutical product, has provided important insights for clinical development.

About Rock Creek Pharmaceuticals, Inc.:                 Rock Creek Pharmaceuticals, Inc. is an emerging drug development company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for chronic inflammatory disease, neurologic disorders and behavioral health.

For more information, visit: http://www.rockcreekpharmaceuticals.com

Forward Looking Statements:

Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and approval of anti-inflammatory drug candidates, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices and the outcome of the ongoing investigations as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2013 filed on March 17, 2014 and our latest 10-Q Report filed on August 11, 2014. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.

CONTACT:

Ted JenkinsVice President, Corporate Strategy, Development, Investor RelationsRock Creek Pharmaceuticals            2040 Whitfield Avenue, Suite 300           Sarasota, FL  34243              Direct: 941-251-0488tjenkins@rockcreekpharmaceuticals.com

Stephanie Carrington             Investors                Integrated Corporate Relations, Inc. (ICR): Redefining Strategic Communications            685 Third Avenue, 2nd Floor,          New York, NY 10017              (646) 277-1282               stephanie.carrington@icrinc.com

Logo – http://photos.prnewswire.com/prnh/20141121/160211LOGO
SOURCE Rock Creek Pharmaceuticals, Inc.

Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015

November 21, 2014 – 6:30 am | Edit Post

SARASOTA, Fla., Nov. 21, 2014 /PRNewswire/ – Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company is scheduled to present at the Biotech Showcase™ 2015 taking place in San Francisco, CA on January 12-14, 2015.

Michael Mullan, MBBS, PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will present preclinical and clinical data for anatabine citrate, a small molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. Dr. Mullan will outline the Company’s regulatory strategy and ongoing drug development initiatives designed to advance its the lead molecule into phase I and phase II trials.

About Biotech Showcase 2015:

Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week, which is widely viewed as setting the tone for the coming year.

About Anatabine Citrate:

Rock Creek Pharmaceuticals’ anatabine citrate is a small molecule, cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. The Company has sponsored extensive pre-clinical (in vitro and in vivo) studies resulting in peer reviewed and published scientific journal articles, covering models of Multiple Sclerosis, Alzheimer’s Disease, and Auto-Immune Thyroiditis. All these studies demonstrated the anti-inflammatory effects of anatabine. In addition, the Company’s compilation of human exposure, safety and tolerability data, derived primarily from human clinical studies and post-marketing data collection of the previously marketed nutraceutical product, has provided important insights for clinical development.

About Rock Creek Pharmaceuticals, Inc.:                 Rock Creek Pharmaceuticals, Inc. is an emerging drug development company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for chronic inflammatory disease, neurologic disorders and behavioral health.

For more information, visit: http://www.rockcreekpharmaceuticals.com

Forward Looking Statements:

Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and approval of anti-inflammatory drug candidates, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices and the outcome of the ongoing investigations as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2013 filed on March 17, 2014 and our latest 10-Q Report filed on August 11, 2014. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.

CONTACT:

Ted JenkinsVice President, Corporate Strategy, Development, Investor RelationsRock Creek Pharmaceuticals            2040 Whitfield Avenue, Suite 300           Sarasota, FL  34243              Direct: 941-251-0488tjenkins@rockcreekpharmaceuticals.com

Stephanie Carrington             Investors                Integrated Corporate Relations, Inc. (ICR): Redefining Strategic Communications            685 Third Avenue, 2nd Floor,          New York, NY 10017              (646) 277-1282               stephanie.carrington@icrinc.com

Logo – http://photos.prnewswire.com/prnh/20141121/160211LOGO
SOURCE Rock Creek Pharmaceuticals, Inc.